Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xoma ( (XOMA) ) has issued an update.
On August 11, 2025, XOMA Royalty Corporation completed its merger with Turnstone Biologics Corp., following a successful tender offer for Turnstone’s outstanding shares. This merger, executed without requiring a stockholder vote, positions XOMA as the sole owner of Turnstone, potentially enhancing its market position and operational capabilities in the biotechnology sector.
The most recent analyst rating on (XOMA) stock is a Buy with a $104.00 price target. To see the full list of analyst forecasts on Xoma stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
Xoma’s overall stock score reflects a mixed financial performance with potential for recovery, but significant risks remain due to profitability challenges and high debt reliance. Technical analysis provides some positive signals, but valuation concerns weigh heavily on the score.
To see Spark’s full report on XOMA stock, click here.
More about Xoma
XOMA Royalty Corporation operates in the biotechnology industry, focusing on royalty monetization and acquisition. The company primarily deals with acquiring potential future cash flows from pharmaceutical and biotechnology products.
Average Trading Volume: 57,799
Technical Sentiment Signal: Buy
Current Market Cap: $381.9M
Find detailed analytics on XOMA stock on TipRanks’ Stock Analysis page.